Abecma’s review was delayed after the FDA rejected a first filing in May last year, but it’s hoped that the drug could be a significant step forward in the treatment of this incurable condition.

2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

Abecma US Revenue: $77 million in the third quarter, reflecting a 42% growth over the prior quarter. Projected Abecma US Revenue for 2024: Approximately $240 to $250 million. Collaboration Arrangement ...

The study is evaluating Abecma (idecabtagene vicleucel; ide-cel) with Revlimid (lenalidomide) maintenance versus lenalidomide ...

The FDA has not yet assigned a new target action date for the review of the supplemental biologics licence application (sBLA) for Abecma for this patient population of triple-class exposed r/r MM.

CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

“Abecma continues to show encouraging signs of growth with an expanded label in the third line and a differentiated safety profile. Consistent with our focus on capital allocation and creating ...

The firm acknowledged that 2Seventy Bio's third-quarter sales of its Abecma product in the United States, reported at $77 million, exceeded the consensus estimates of $70 million. The company also ...

The latest announcement is out from 2seventy bio ( (TSVT) ). 2seventy bio reported impressive third-quarter results with a 42% increase in ...